Recomendaciones SER sobre la gestión de riesgo del tratamiento con FAME biológicos o sintéticos dirigidos en pacientes con artritis reumatoide

IF 1.2 Q4 RHEUMATOLOGY

Reumatologia Clinica Pub Date : 2023-10-06 DOI:10.1016/j.reuma.2023.07.001

Alejandro Balsa , Petra Díaz del Campo Fontecha , Lucía Silva Fernández , José Valencia Martín , Virginia Nistal Martínez , Fernando León Vázquez , M. Vanesa Hernández Hernández , Héctor Corominas , Rafael Cáliz Cáliz , José María Aguado García , Gloria Candelas Rodríguez , Nora Ibargoyen Roteta , Arturo Martí Carvajal , M. Nieves Plana Farras , Janet Puñal Riobóo , Hye Sang Park , Yolanda Triñanes Pego , Virginia Villaverde García

{"title":"Recomendaciones SER sobre la gestión de riesgo del tratamiento con FAME biológicos o sintéticos dirigidos en pacientes con artritis reumatoide","authors":"Alejandro Balsa , Petra Díaz del Campo Fontecha , Lucía Silva Fernández , José Valencia Martín , Virginia Nistal Martínez , Fernando León Vázquez , M. Vanesa Hernández Hernández , Héctor Corominas , Rafael Cáliz Cáliz , José María Aguado García , Gloria Candelas Rodríguez , Nora Ibargoyen Roteta , Arturo Martí Carvajal , M. Nieves Plana Farras , Janet Puñal Riobóo , Hye Sang Park , Yolanda Triñanes Pego , Virginia Villaverde García","doi":"10.1016/j.reuma.2023.07.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To present recommendations based on the available evidence and the consensus of experts, for risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis.</p></div><div><h3>Methods</h3><p>Clinical research questions relevant to the purpose of the document were identified. These questions were reformulated in PICO format (patient, intervention, comparison, outcome) by a panel of experts, selected based on their experience in the area. A systematic review of the evidence was carried out, grading according to the GRADE criteria (Grading of Recommendations Assessment, Development, and Evaluation). Specific recommendations were then formulated.</p></div><div><h3>Results</h3><p>Six PICO questions were proposed by the panel of experts based on their clinical relevance and the existence of recent information regarding the risk of occurrence of serious infections, the risk of reactivation of the hepatitisB virus, the risk of reactivation of the virus varicella-zoster, the risk of appearance of skin (melanoma and non-melanoma) or hematological cancer, the risk of appearance of thromboembolic disease and the risk of progression of the human papilloma virus.</p><p>A total of 29 recommendations were formulated, structured by question, based on the evidence found and the consensus of the experts.</p></div><div><h3>Conclusions</h3><p>The SER recommendations on risk management of treatment with biologic therapies and JAK inhibitors in rheumatoid arthritis are presented.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"19 10","pages":"Pages 533-548"},"PeriodicalIF":1.2000,"publicationDate":"2023-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reumatologia Clinica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1699258X23001729","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

To present recommendations based on the available evidence and the consensus of experts, for risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis.

Methods

Clinical research questions relevant to the purpose of the document were identified. These questions were reformulated in PICO format (patient, intervention, comparison, outcome) by a panel of experts, selected based on their experience in the area. A systematic review of the evidence was carried out, grading according to the GRADE criteria (Grading of Recommendations Assessment, Development, and Evaluation). Specific recommendations were then formulated.

Results

Six PICO questions were proposed by the panel of experts based on their clinical relevance and the existence of recent information regarding the risk of occurrence of serious infections, the risk of reactivation of the hepatitis B virus, the risk of reactivation of the virus varicella-zoster, the risk of appearance of skin (melanoma and non-melanoma) or hematological cancer, the risk of appearance of thromboembolic disease and the risk of progression of the human papilloma virus.

A total of 29 recommendations were formulated, structured by question, based on the evidence found and the consensus of the experts.

Conclusions

The SER recommendations on risk management of treatment with biologic therapies and JAK inhibitors in rheumatoid arthritis are presented.

查看原文本刊更多论文

关于类风湿关节炎患者靶向生物或合成FAME治疗风险管理的建议

目的根据现有证据和专家共识，为类风湿性关节炎患者的生物治疗和JAK抑制剂的风险管理提出建议。方法明确与文献目的相关的临床研究问题。这些问题由一个专家小组根据他们在该领域的经验重新制定为PICO格式（患者、干预、比较、结果）。对证据进行了系统审查，根据GRADE标准（建议评估、制定和评估的分级）进行了分级。随后制定了具体建议。结果专家组根据其临床相关性和最近关于严重感染发生风险、乙型肝炎病毒再激活风险、水痘-带状疱疹病毒再激活的风险、皮肤（黑色素瘤和非羊毛瘤）或血液癌症出现的风险的信息，提出了6个PICO问题，血栓栓塞性疾病出现的风险和人类乳头状瘤病毒进展的风险。根据所发现的证据和专家们的共识，按问题提出了总共29项建议。结论SER对类风湿性关节炎生物疗法和JAK抑制剂治疗的风险管理提出了建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Reumatologia Clinica RHEUMATOLOGY-

CiteScore

2.40

自引率

6.70%

发文量

105

审稿时长

54 days

期刊介绍： Una gran revista para cubrir eficazmente las necesidades de conocimientos en una patología de etiología, expresividad clínica y tratamiento tan amplios. Además es La Publicación Oficial de la Sociedad Española de Reumatología y del Colegio Mexicano de Reumatología y está incluida en los más prestigiosos índices de referencia en medicina.